Early preclinical studies suggested MK-1775 was capable of abrogating the G2/M checkpoint allowing for premature entry into mitosis to exert a toxic effect specifically in p53 deficient tumor cells (Guertin et al., 2013; Hirai et al., 2014). Here, TP53 is linked to neoplasm.